Finnishconsumer genetic testing firm Negen has turned to BC Platforms for analysis ofraw genomic data for clinical reporting purposes, the companies announced recently.
Underterms of the new partnership, BC Platforms will run data collected by Negenthrough its data management system to inform Negen's risk-scoring algorithms.Further terms were not disclosed.
Negen offers specific tests for diabetes and cardiovasculardisease risk based on genomic and lifestyle factors. These tests, as well as ageneral screening for rare hereditary conditions, are intended to informclinicians in recommending treatments and lifestyle changes, the companysaid.
"This partnership will greatlyincrease the awareness and utility of our genetic risk-scoring tools and ourautomatized genetic data interpretation," Negen CEO Kimmo Aro said ina statement.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.